Physician profile
Leonid Basovich
NPI 1285626515
$5,733.32
in general payments reported to CMS, 2019-2025
28 companies · $899 in 2025
The $899 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2021: $543 · 2022: $1,013 · 2023: $1,854 · 2024: $1,155 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,908.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,026.16 | 2021-2025 | Creon, Linzess, Viberzi |
| Bayer Healthcare Pharmaceuticals INC. | $537.51 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $489.96 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $438.50 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $400.47 | 2021-2025 | Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $395.73 | 2024-2025 | Zenpep, Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.33 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $246.85 | 2019-2023 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $245.46 | 2023 | Dupixent |
| Amgen INC. | $229.01 | 2023 | Repatha |
| Janssen Pharmaceuticals, INC | $223.98 | 2022-2024 | Spravato |
| Glaxosmithkline, LLC. | $164.84 | 2021-2023 | Nucala, Arexvy, Shingrix |
| Exact Sciences Corporation | $158.85 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Medtronic Vascular, INC. | $132.26 | 2019 | |
| Nestle Healthcare Nutrition INC. | $126.55 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $125.87 | 2023 | |
| Hologic Sales and Service, LLC | $109.05 | 2019-2025 | Aptima |
| Abbott Laboratories | $60.06 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $42.49 | 2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $39.30 | 2024-2025 | Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $36.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $23.41 | 2023 | Nuedexta |
| Kowa Pharmaceuticals America, INC. | $23.22 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.67 | 2025 | Xifaxan |
| Boston Scientific Corporation | $19.30 | 2023 | Varithena Administration Pack |
| Pfizer INC. | $17.82 | 2025 | |
| Scilex Pharmaceuticals INC. | $15.38 | 2023 | Ztlido |
| Alfasigma USA, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Basovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.